Supplementary Online Content

Weidhaas JB, Harris J, Schaue D, et al. The *KRAS*-variant and cetuximab response in head and neck squamous cell cancer: a secondary analysis of a randomized clinical trial. *JAMA Oncol.* Published online December 22, 2016. doi:10.1001/jamaoncol.2016.5478

eTable 1. Pretreatment Characteristics by Whether or Not KRAS Genotype Is Known

eTable 2. Pretreatment Characteristics by KRAS Genotype and Assigned Treatment

eTable 3. TGFB1 by p16 and KRAS-Variant Status

eTable 4. Grade 3-4 Treatment-Related [1] Radiation Mucositis by *KRAS*-Variant and Assigned Treatment

eTable 5. Grade 3-4 Treatment-Related [1] Skin Reaction Inside Portal [2] by *KRAS*-Variant and Assigned Treatment

eTable 6. Grade 3-4 Treatment-Related [1] Skin Reaction Outside Portal [2] by *KRAS*-Variant and Assigned Treatment

eFigure 1. CONSORT Flow Diagram RTOG 0522

eFigure 2. Distant Metastasis

eFigure 3. Local Regional Failure

This supplementary material has been provided by the authors to give readers additional information about their work.

	KRAS geno		
—	Yes	No	
	(n=413)	(n=478)	p-value
Assigned treatment			1.00 43
No cetuximab	207 (50.1%)	240 (50.2%)	
Cetuximab	206 (49.9%)	238 (49.8%)	
Age (years)			0.02 [3]
Mean	57.5	56.3	
Std. Dev.	7.88	8.36	
Median	58	56	
Min - Max	31 - 77	34 - 79	
Q1 - Q3	52 - 63	50 - 62	
Gender			0.76 43
Male	366 (88.6%)	420 (87.9%)	
Female	47 (11.4%)	58 (12.1%)	
Race			0.13 43
White	382 (92.5%)	428 (89.5%)	
Non-white	31 (7.5%)	50 (10.5%)	
Zubrod performance status			0.09 43
0	260 (63.0%)	327 (68.4%)	
1	153 (37.0%)	151 (31.6%)	
Smoking history: pack-years [1]	(n=367)	(n=404)	0.93 [3]
Mean	27.4	27.8	0.20 [0]
Std. Dev.	27.50	28.75	
Median	23.5	20.7	
Min - Max	0 - 162	0 - 150	
Q1 - Q3	1 - 42	0.1 - 44.9	

eTable 1. Pretreatment Characteristics by Whether or Not KRAS Genotype Is Known

 $\ensuremath{\mathbb{C}}$ 2016 American Medical Association. All rights reserved.

	KRAS geno		
-	Yes	No	
	(n=413)	(n=478)	p-value
Primary site			0.24 43
Oropharynx	298 (72.2%)	327 (68.4%)	
Hypopharynx/larynx	115 (27.8%)	151 (31.6%)	
p16 status (oropharynx only)	(n=188)	(n=133)	0.37 43
p16-negative	54 (28.7%)	32 (24.1%)	
p16-positive	134 (71.3%)	101 (75.9%)	
T stage			0.33 [3]
T2	170 (41.2%)	181 (37.9%)	
T3	149 (36.1%)	180 (37.7%)	
T4	94 (22.8%)	117 (24.5%)	
N stage			0.79 [3]
NO	46 (11.1%)	53 (11.1%)	
N1	36 (8.7%)	45 (9.4%)	
N2a	37 (9.0%)	41 (8.6%)	
N2b	139 (33.7%)	154 (32.2%)	
N2c	137 (33.2%)	159 (33.3%)	
N3	18 (4.4%)	26 (5.4%)	

eTable 1. Pretreatment Characteristics by Whether or Not KRAS Genotype Is Known

Std. Dev. = standard deviation; Q1 = first quartile; Q3 = third quartile.

[1] A pack-year is defined as the equivalent of smoking one pack of cigarettes a day for 1 year.

⁴³ Fisher's exact test.

[3] Wilcoxon rank-sum test.

	Non-vari	ant (TT)	KRAS-variant (GG/TG)		
-	No Cetuximab Cetuximab		No Cetuximab	Cetuximab	
	(n=169)	(n=174)	(n=38)	(n=32)	
Age (years)	p=0.05		p=0.	.22	
Mean	56.7	58.5	57.6	55.6	
Standard deviation	8.19	7.59	8.29	6.81	
Median	57	59	58	54.5	
Min - Max	31 - 77	41 - 76	38 - 75	42 - 69	
Q1 - Q3	52 - 62	53 - 64	53 - 63	51 - 61	
Gender	p=0	.31	p=0.	.44	
Male	146 (86.4%)	157 (90.2%)	33 (86.8%)	30 (93.8%)	
Female	23 (13.6%)	17 (9.8%)	5 (13.2%)	2 (6.3%)	
Ethnicity	p=0	.69	p=0	.04	
White	157 (92.9%)	159 (91.4%)	38 (100.0%)	28 (87.5%)	
Non-white	12 (7.1%)	15 (8.6%)	0 (0.0%)	4 (12.5%)	
Zubrod performance status	p=0	.74	p=1.00		
0	109 (64.5%)	109 (62.6%)	23 (60.5%)	19 (59.4%)	
1	60 (35.5%)	65 (37.4%)	15 (39.5%)	13 (40.6%)	
Smoking history: pack-years [1]	p=0	.69	p=0.14		
	(n=150)	(n=154)	(n=35)	(n=28)	
Mean	26.5	26.7	35.1	26.8	
Standard deviation	26.08	29.24	26.52	26.10	
Median	27.25	17.8	34	20.5	
Min - Max	0 - 150	0 - 162	0 - 90	0 - 110	
Q1 - Q3	1.35 - 40	0 - 42	4.5 - 51	3 - 40.35	
Primary site	p=0.47		p=0.79		
Oropharynx	118 (69.8%)	128 (73.6%)	29 (76.3%)	23 (71.9%)	
Hypopharynx/larynx	51 (30.2%)	46 (26.4%)	9 (23.7%)	9 (28.1%)	

eTable 2. Pretreatment Characteristics by KRAS Genotype and Assigned Treatment

 $\ensuremath{\mathbb{C}}$ 2016 American Medical Association. All rights reserved.

	Non-vari	ant (TT)	KRAS-variant (GG/TG)		
	No Cetuximab Cetuximal		No Cetuximab	Cetuximab	
	(n=169)	(n=174)	(n=38)	(n=32)	
p16 status (all sites)	p=0	.59	p=0.14		
	(n=108)	(n=118)	(n=22)	(n=23)	
p16-negative	50 (46.3%)	50 (42.4%)	13 (59.1%)	8 (34.8%)	
p16-positive	58 (53.7%)	68 (57.6%)	9 (40.9%)	15 (65.2%)	
T stage	p=0	.39	p=0	.24	
T2	64 (37.9%)	74 (42.5%)	16 (42.1%)	16 (50.0%)	
Т3	64 (37.9%)	62 (35.6%)	11 (28.9%)	12 (37.5%)	
T4	41 (24.3%)	38 (21.8%)	11 (28.9%)	4 (12.5%)	
N stage	p=0	.07	p=0.12		
N0	11 (6.5%)	23 (13.2%)	5 (13.2%)	7 (21.9%)	
N1	19 (11.2%)	14 (8.0%)	1 (2.6%)	2 (6.3%)	
N2a	11 (6.5%)	19 (10.9%)	4 (10.5%)	3 (9.4%)	
N2b	57 (33.7%)	58 (33.3%)	12 (31.6%)	12 (37.5%)	
N2c	63 (37.3%)	54 (31.0%)	13 (34.2%)	7 (21.9%)	
N3	8 (4.7%)	6 (3.4%)	3 (7.9%)	1 (3.1%)	

eTable 2. Pretreatment Characteristics by KRAS Genotype and Assigned Treatment

Q1 = first quartile; Q3 = third quartile.

[1] A pack-year is defined as the equivalent of smoking one pack of cigarettes a day for 1 year.

[P-values for age, pack-years, T stage, and N stage are from Wilcoxon rank-sum test.

P-values for gender, race, Zubrod performance status, primary site, and p16 status are from Fisher's exact test.

eTable 3. TGFB1 by p16 and KRAS-Variant Status

	n	Min	Q1	Median	Q3	Max
p16-negative, KRAS-non-variant	91	2757.51	10155.76	18989.05	28145.41	121030.02
p16-positive, KRAS-non-variant	117	2261.42	7740.52	15284.42	32292.91	119449.13
p16-negative, KRAS-variant	20	5034.35	13106.36	23254.16	43662.46	97677.11
p16-positive, KRAS-variant	23	5070.55	10152.63	20083.48	53024.57	85081.77

(p=0.34 by Kruskal-Wallis test)

				Odds Ratio
KRAS	Assigned Treatment	Patients	Events	(95% Confidence Interval)
NT		1.00		
Non-variant	No cetuximab	169	64 (37.9%)	Reference
	Cetuximab	174	88 (50.6%)	1.68 (1.09-2.58)
				p=0.02
Variant	No cetuximab	38	18 (47.4%)	Reference
	Cetuximab	32	16 (50.0%)	1.11 (0.43-2.85)
				p=0.83
Total		413	186 (45.0%)	interaction p=0.43

eTable 4. Grade 3-4 Treatment-Related [1] Radiation Mucositis by *KRAS*-Variant and Assigned Treatment

Odds ratios estimated from logistic regression model with covariates KRAS (variant vs. Non-variant), treatment (cetuximab vs. no cetuximab) and the interaction of KRAS and treatment.

[1] Definitely, probably, or possibly related to protocol treatment.

KRAS	Assigned Treatment	Patients	Events	Odds Ratio (95% Confidence Interval)
Non-variant	No cetuximab	169	19 (11.2%)	Reference
	Cetuximab	174	38 (21.8%)	2.21 (1.21-4.01) p=0.01
Variant	No cetuximab	38	7 (18.4%)	Reference
	Cetuximab	32	5 (15.6%)	0.82 (0.23-2.89) p=0.76
Total		413	69 (16.7%)	interaction p=0.16

eTable 5. Grade 3-4 Treatment-Related [1] Skin Reaction Inside Portal [2] by *KRAS*-Variant and Assigned Treatment

Odds ratios estimated from logistic regression model with covariates KRAS (variant vs. Non-variant), treatment (cetuximab vs. no cetuximab) and the interaction of KRAS and treatment.

[1] Definitely, probably, or possibly related to protocol treatment.

[2] Dermatitis radiation NOS; Radiation recall syndrome.


KRAS	Assigned Treatment	Patients	Events	Odds Ratio (95% Confidence Interval)
Non-variant	No cetuximab	169	1 (0.6%)	Reference
	Cetuximab	174	40 (23.0%)	50.15 (6.81-369.54) p<0.001
Variant	No cetuximab	38	1 (2.6%)	Reference
	Cetuximab	32	6 (18.8%)	8.54 (0.97-75.20) p=0.05
Total		413	48 (11.6%)	interaction p=0.24

eTable 6. Grade 3-4 Treatment-Related [1] Skin Reaction Outside Portal [2] by *KRAS*-Variant and Assigned Treatment


Odds ratios estimated from logistic regression model with covariates KRAS (variant vs. Nonvariant), treatment (cetuximab vs. no cetuximab) and the interaction of KRAS and treatment. [1] Definitely, probably, or possibly related to protocol treatment.

[2] Pruritis; Dermatitis exfoliative NOS; Acne NOS; Nail disorder NOS.

eFigure 1. CONSORT Flow Diagram RTOG 0522



eFigure 2. Distant metastasis



eFigure 3. Local Regional Failure

